Bruna de Camargo Nigro

Bruna de Camargo Nigro

Auto-generated profile, based on publicly available information

Bruna de Camargo Nigro

Instituto do Câncer do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
PDF file
FTFlávio Roberto Takeda
Flávio Roberto Takeda
Francisco TustumiFrancisco Tustumi
Francisco Tustumi
BNBruna de Camargo Nigro
Bruna de Camargo Nigro
RSRubens Antonio Aissar Sallum
Rubens Antonio Aissar Sallum
URUlysses Ribeiro-Junior
Ulysses Ribeiro-Junior
ICIvan Cecconello
Ivan Cecconello
Background: Esophageal cancer neoadjuvant therapy followed by surgery increases the likelihood of treatment success. Aim: To evaluate variables that can influence the number of retrieved lymph nodes, the number of retrieved metastatic lymph nodes and lymphnodal recurrence in esophagectomy after neoadjuvant chemoradiotherapy. Methods: Patients of a single institute were evaluated after completion of trimodal therapy. Univariate and multivariate analyses were performed to evaluate variables that can influence in the number of retrieved lymph nodes and retrieved metastatic lymph nodes. Results: One hundred and forty-nine patients were included. Thoracoscopy access was considered an independent factor for the number of lymph nodes retrieved, but was neither related to the number of positive lymph nodes retrieved nor to lymphnodal recurrence. Pathological complete response on the primary tumor and male were independent variables associated with the number of positive lymph node retrieved. Pathological complete response on the primary tumor site did not statistically influence the likelihood of a lower number of lymph nodes retrieved. Conclusion: Patients submitted to esophagectomy after neoadjuvant chemoradiotherapy, thoracoscopic access is more accurate for pathological staging, even in a complete pathological response. With a proper patient selection, transhiatal surgery may preserve the quality of lymphadenectomy of the positive lymph nodes.

21 November 2025 in Clinics
Verified
Journal Article
Open access
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
ADAndre Roncon Dias
Andre Roncon Dias
OYOsmar Kenji Yagi
Osmar Kenji Yagi
BNBruna de Camargo Nigro
Bruna de Camargo Nigro
URUlysses Ribeiro-Junior
Ulysses Ribeiro-Junior
The treatment of Gastric Cancer (GC) has evolved with advances in multimodal therapy and minimally invasive surgery. This study aimed to provide an overview of the current treatment and survival outcomes of GC at a public high-volume cancer center during 15 years. Patients with gastric adenocarcinoma who underwent any surgical procedure between January 2009 and December 2023 were retrospectively included. To investigate temporal differences in patient characteristics and therapeutic approaches, the case cohort was divided into two time periods: Period I (2009-2016) and II (2016-2023). A total of 1406 patients were included: 741 (52.7 %) were treated in Period I, and 665 (47.3 %) in Period II. The proportion of curative-intent surgeries remained stable (65.2% vs. 65.1), but diagnostic procedures increased (7.3 % vs. 12.2). Overall, 804 (57.2 %) patients underwent potentially curative gastrectomy. In Period II, patients had advanced ASA scores, more advanced clinical staging, and more frequent D1 lymphadenectomy (all p < 0.05). The use of minimally invasive surgery and the number of resected lymph nodes increased (both p < 0.001). Multimodal treatment became more frequent, with increased use of preoperative chemotherapy (p = 0.03). There were no significant differences in postoperative complications or 30- and 90-day mortality rates between the two periods. In multivariable analysis, advanced age, ASA III/IV, total gastrectomy, D1 lymphadenectomy, diffuse/mixed histology, advanced pT stage, and lymph node metastasis were independent factors associated with worse survival (all p < 0.05). Over 15 years, treatment evolved toward increased use of minimally invasive and multimodal approaches, with no impact on short-term surgical outcomes.

1 January 2025 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
MRMateus Barradas Ribeiro
Mateus Barradas Ribeiro
Marina Alessandra PereiraMarina Alessandra Pereira
Marina Alessandra Pereira
DMDonato Roberto Mucerino
Donato Roberto Mucerino
OYOsmar Kenji Yagi
Osmar Kenji Yagi
ADAndré Roncon Dias
André Roncon Dias
Marcus F. Kodama P. RamosMarcus F. Kodama P. Ramos
Marcus F. Kodama P. Ramos
Background: Gastric neuroendocrine tumors (gNETs) are uncommon neoplasms arising from enterochromaffin-like cells, representing a distinct subset of gastric malignancies, with challenging clinical management. Aims: To analyse the classification, treatment indication, and survival of patients diagnosed with gNETs. Methods: We retrospectively analyzed patients diagnosed with gNETs between 2009 and 2025 at a high-volume tertiary center in Brazil. Clinical, pathological, and treatment data were reviewed, and tumors were classified according to World Health Organization and clinicopathological criteria into Types I, II, and III. Results: Of the 75 patients included, 53 (70.7%) were classified as Type I, 5 (6.7%) as Type II, and 17 (22.6%) as Type III. Treatment included surgery in 25 patients (33.3%) and endoscopic resection in 50 (66.7%). Type I tumors predominated in females (p<0.001), were frequently multifocal (p<0.001), associated with higher body mass index (p=0.002), and were mainly managed endoscopically (p=0.008). Type II tumors were rare and associated with multiple endocrine neoplasia Type 1, while Type III tumors were predominantly male, larger, high-grade (G3), and frequently metastatic, requiring surgical resection and palliative therapy. Among the 25 surgically treated patients, most were men (52%) and included 12 patients (48.0%) with Type I, 3 (12.0%) with Type II, and 10 (40.0%) with Type III tumors. Survival analysis showed significantly worse outcomes for Type III and G3 tumors. Multivariable analysis identified advanced age (hazards ratio 4.11; 95% confidence interval (95%CI): 1.14–14.80; p=0.030) and tumor, lymph node, metastasis (TNM) stage III/IV (HR 5.42; 95%CI: 1.26–23.26; p=0.023) as independent predictors of poorer survival. Conclusions: gNETs exhibit heterogeneous clinical behavior, with Type I tumors predominating in the Brazilian population. Tumor type, grade, and TNM stage are critical determinants of prognosis and should guide individualized treatment strategies.